Efficacy and tolerance of tacrolimus and pimecrolimus for atopic dermatitis: A meta-analysis

5Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

Tacrolimus ointment and pimecrolimus cream have proved to be suitable for the treatment of atopic dermati-tis. We conducted a meta-analysis of the efficacy, adverse events/withdrawal of tacrolimus versus pimecrolimus in the treatment of atopic dermatitis. According to our meta-analysis, 0.1% tacrolimus was more effective than 1% pimecrolimus in the treatment of adult patients and moderate to very severe pediatric patients, and more 0.1% mild pediatric patients treatal with pimecrolimus withdrew from the trials because of a lack of efficacy or the oc-currence of adverse events, compared with mild pediatric patients treated with 0.03% tacrolimus. The combined analyses of tacrolimus with pimecrolimus showed that tacrolimus was more effective than pimecrolimus (week 3: RR=0.67, 95%CI=0.56-0.80; week 6/end of study: RR=0.65, 95%CI=0.57-0.75), and fewer tacrolimus-treated patients withdrew because of a lack of efficacy (RR=0.32, 95CI% =0.19-0.53) or the occurrence of adverse events (RR=0.43, 95%CI=0.24-0.75), compared with pimecrolimus-treated patients. In conclusion, tacrolimus has higher efficacy and better tolerance than pimecrolimus in the treatment of atopic dermatitis. © 2011 The Editorial Board of Journal of Biomedical Research.

Cite

CITATION STYLE

APA

Yin, Z., Xu, J., & Luo, D. (2011). Efficacy and tolerance of tacrolimus and pimecrolimus for atopic dermatitis: A meta-analysis. Journal of Biomedical Research, 25(6), 385–391. https://doi.org/10.1016/S1674-8301(11)60051-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free